Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sen. Burr Worries Rising User Fees Helping US FDA Evade Congressional Oversight

Burr Had Raised Questions During 2017 Reauthorization Cycles

Executive Summary

Burr wants more FDA accountability in the new user fee agreements and questions whether they benefit patients. Generic approval modifications get attention at hearing.

You may also be interested in...



US FDA’s Accelerated Approval Reforms Include Dispute Resolution For Withdrawals

Allowing decisions to be reviewed by higher management levels, rather than convening administrative hearings, could save time in the withdrawal process.

FDA Seeks Input On Inactive Ingredients Database

Industry input is being sought by the FDA on its inactive ingredient database, as the US agency considers how to prioritize the addition of maximum daily exposure limits as well as mulling the removal of specific dosage form information.

Biden Requests US FDA Budget Surge: Pandemic Preparedness Money Would Increase Funding 36%

President Biden’s budget request would add $1.63bn in mandatory funding to the FDA budget in FY 2023.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

GB151795

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel